JGC
LJPC

J. Goldman & Co’s La Jolla Pharmaceutical Company LJPC Stock Holding History

J. Goldman & Co’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-55,300
Closed -$1.65M – 522
2018
Q1 		$1.65M Buy
+55,300
New +$1.78M 0.07% 228

Other funds holding LJPC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

J. Goldman & Co's LJPC Position: Q2 2018 in Review

J. Goldman & Co sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2018, closing a stake of 55,300 shares — an estimated $1.65M sold.

J. Goldman & Co first reported a position in LJPC in Q1 2018 and held it in 1 quarter. The position peaked at $1.65M in Q1 2018. 95 funds tracked by Wall St. Rank hold LJPC as of Q2 2018.

  • J. Goldman & Co reported no remaining La Jolla Pharmaceutical Company position as of Q2 2018 after selling out during the quarter.
  • J. Goldman & Co sold 55,300 La Jolla Pharmaceutical Company shares in Q2 2018, an estimated $1.65M.
  • J. Goldman & Co first reported a position in La Jolla Pharmaceutical Company in Q1 2018 and held it in 1 quarter.
  • J. Goldman & Co's La Jolla Pharmaceutical Company position peaked at $1.65M in Q1 2018.
  • 95 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.